Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy

Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial

Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

US FDA approves Scholar Rock's muscle weakness drug

Scholar Rock drops Catalent facility from marketing application for muscle weakness drug

Scholar Rock says EU opinion on SMA drug may be pushed to later in 2026